FDA Releases Guidances on Dual 510(k)-CLIA Waiver Submissions

Clinical Trials Advisor
The FDA issued two draft guidances to encourage using the 510(k)-Clinical Laboratory Improvement Amendments (CLIA) waiver dual application pathway for new in vitro diagnostic devices, and to update its policies for demonstrating accuracy to obtain a CLIA designation.

To View This Article:


Subscribe To Clinical Trials Advisor